Mitomycin Accord (Mitomycin)

Mitomycin is a bioreductive alkylating agent that forms DNA cross‑links after activation in hypoxic tumour cells. These cross‑links block DNA replication and transcription, leading to programmed cell death of rapidly dividing cancer cells.

The dosage of Mitomycin Accord is individualized by the prescribing oncologist based on the specific cancer type, treatment regimen, patient weight, renal function and other clinical factors. No standard dose is provided here.

Mitomycin is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant. Use only if the potential benefit justifies the risk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with other alkylating agents, mitomycin has a unique activation in low‑oxygen environments, making it effective against hypoxic tumour regions. Its toxicity profile includes notable renal and pulmonary risks, which differ from agents such as cyclophosphamide that have distinct organ‑specific side effects.

Mitomycin Accord should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the product. Prior to administration, reconstitute according to the manufacturer’s instructions in a sterile environment.

Mitomycin Accord is given by intravenous infusion under the supervision of qualified healthcare professionals. The infusion rate and duration are determined by the treating physician and may be adjusted based on patient tolerance and response.

Serious risks include severe myelosuppression, pulmonary fibrosis, renal failure, hemolytic‑uremic syndrome and rare secondary malignancies. Patients should be monitored closely for signs of infection, respiratory difficulty, renal impairment and abnormal blood counts.

Mitomycin is contraindicated in patients with known hypersensitivity to mitomycin or related compounds, in those with severe renal or hepatic impairment, and in pregnant or nursing women unless the therapeutic benefit outweighs the potential risk.